Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2017, Vol.4 (4), p.ofx202-ofx202
Hauptverfasser: Zimmerman, Ofer, Rösler, Berenice, Zerbe, Christa S, Rosen, Lindsey B, Hsu, Amy P, Uzel, Gulbu, Freeman, Alexandra F, Sampaio, Elizabeth P, Rosenzwieg, Sergio D, Kuehn, Hye Sun, Kim, Tiffany, Brooks, Kristina M, Kumar, Parag, Wang, Xiaowen, Netea, Mihai G, van de Veerdonk, Frank L, Holland, Steven M
Format: Artikel
Sprache:eng
Schlagworte:
Brief Report
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofx202